Novo Nordisk promoted Maziar Mike Doustdar to president and CEO, effective August 7. The Food and Drug Administration tapped newly appointed George Tidmarsh as acting Center for Biologics Evaluation ...

The presence of George Osborne at Robey Warshaw, and the payouts to partners following the £146m sale to Evercore, is certain ...

Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

In terms of its transformative effect, AI is doing for healthcare what electricity did for the industry. According to Fortune ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

The UK’s largest listed companies are turning their heads towards the glimmer of the Nasdaq after growing impatient ...

AstraZeneca PLC AZN has struck a deal to buy a portfolio of gene therapies from Pfizer Inc. PFE for up to $1 billion, the biopharma company announced Friday. The deal, expected to close in the ...

GSK lifted profit guidance for the year on Wednesday after sales of the drugmaker's 'specialty' medicines soared.

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...